|
Status |
Public on Jul 18, 2017 |
Title |
LNCaP_vehicle+R1881_rep3 |
Sample type |
RNA |
|
|
Source name |
LNCaP cells, 48h R1881 treatment
|
Organism |
Homo sapiens |
Characteristics |
cell line: human LNCaP prostate cancer cells (immortalized cell line) : R1881
|
Treatment protocol |
Cells were treated for 48h with R1881 (10nM), Torin 1 (100nM), or vehicles (EtOH+DMSO).
|
Growth protocol |
Cells were seeded in RPMI media with no phenol red and with charcoal-stripped serum (no steroids) . 48h later, cell were treated with 10nM R1881, Torin 1 (100nM) or vehicles (EtOH and DMSO) for 48h. Triplicate samples were sent for each conditions.
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was purified using RNeasy mini kit from QIAGEN
|
Label |
biotin
|
Label protocol |
Labeling was performed using standard Illumina protocol at Génome Québec Innovation Centre (McGill University)
|
|
|
Hybridization protocol |
RNA was hybridized to Illumina HumanHT-12 Expression Beachip v4 and quantified at Génome Québec Innovation Centre (McGill University)
|
Scan protocol |
Scan of the microarrays was performed by the Génome Québec Innovation Centre (McGill University)
|
Description |
vehicler18813
|
Data processing |
The expression data were analyzed using FlexArray10 software. FlexArray10 software was using for data normalization and expression comparison between groups.
|
|
|
Submission date |
Jan 13, 2017 |
Last update date |
Jul 18, 2017 |
Contact name |
Etienne Audet-Walsh |
E-mail(s) |
etienne.audet-walsh@crchudequebec.ulaval.ca
|
Organization name |
Université Laval
|
Department |
Molecular Medicine
|
Street address |
2705 boulevard Laurier
|
City |
Québec City |
State/province |
QC |
ZIP/Postal code |
G1V 4G2 |
Country |
Canada |
|
|
Platform ID |
GPL10558 |
Series (2) |
GSE93603 |
Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer progression [array] |
GSE93846 |
Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer progression |
|